Safety and Durability of Sirolimus for Treatment of LAM

Study summary

The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedSirolimus and Everolimus

The study team can explain what participation involves.

Who it may be forLymphangioleiomyomatosis

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Dec 24, 2024 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Observational

Where is it offered?20 U.S. locations

Locations may change over time.

Who runs it?University of Cincinnati

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: University of Cincinnati
Interventions being studied: Drug: Sirolimus; Drug: Everolimus

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Female or male, age 18 or over
Diagnosis of LAM based on ATS/JRS criteria
Signed and dated informed consent
On chronic therapy, newly treated or may be considered for therapy with mTOR inhibitors or previously intolerant of or having failed mTOR inhibitor therapy

Reasons someone may not be able to joinExclusion criteria

Inability to attend at least one RLD Clinic visit per year
Inability to give informed consent
Inability or unwillingness to perform pulmonary function testing

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Stanford University Medical CenterStanford, California
National Jewish HealthDenver, Colorado
Mayo Clinic JacksonvilleJacksonville, Florida
Emory University School of MedicineAtlanta, Georgia
Loyola University Medical Center, ChicagoMaywood, Illinois
Brigham and Women's HospitalBoston, Massachusetts
University of MichiganAnn Arbor, Michigan
Mayo Clinic RochesterRochester, Minnesota
Washington University School of MedicineSt Louis, Missouri
University of Rochester Medical CenterRochester, New York
University of CincinnatiCincinnati, Ohio
Cleveland ClinicCleveland, Ohio

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 24, 2024. Always confirm current availability with the study team.

View original record ↗